Satellos Bioscience Inc. (TSX:MSCL)

Market Cap	356.23M +194.3%
Revenue (ttm)	n/a
Net Income	-30.04M
EPS	-2.27
Shares Out	20.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,946
Average Volume	32,746
Open	18.61
Previous Close	17.85
Day's Range	16.64 - 18.98
52-Week Range	6.24 - 18.98
Beta	0.68
RSI	66.55
Earnings Date	Mar 27, 2026

About Satellos Bioscience

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British C...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 17
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: MSCL

Financial Performance

Financial numbers in USD